Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Bartsch SM, Umscheid CA, Fishman N, Lee BY. Is fidaxomicin worth the cost? An economic analysis. Clinical Infectious Diseases 2013; 57(4): 555-561 Indexing Status Subject indexing assigned by NLM MeSH Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides /economics /therapeutic use; Anti-Bacterial Agents /economics /therapeutic use; Clostridium Infections /drug therapy /microbiology; Clostridium difficile /isolation & Cost-Benefit Analysis; Female; Health Care Costs; Humans; Male; Middle Aged; Young Adult; purification AccessionNumber 22013021314 Date bibliographic record published 30/04/2014 |